Amiotrófiás laterálszklerózis (ALS): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TDP-43 8
• SOD1 8
• C9orf72 4
• NRF2 0
• STING 0
• SIRT1 0
• HDAC 0
• NLRP3 0
• TREM2 0
• BDNF 0
• MAPK 0
• APOE 0
• GLP-1 0
• HMGB1 0
• mTOR 0
• SMN1 0
• TP53 0
• AMPK 0
• BTK 1
• CXCR4 0
• HSP90 1
• JAK 0
• JNK 0
• LAG-3 0
• NMDA 0
• PI3K 0
• PINK1 0
• PPAR 0
• TFEB 0
• TNF 0
• AKT 0
• APP 0
• ATM 0
• AXL 0
• BCL-2 0
• CDK4/6 0
• COX-2 0
• CSF1R 0
• ERK 0
• GPX4 0
• IL-1 0
• MAPT 0
• PARP 0
• PCSK9 0
• PDE4 1
• PSEN1 0
• PTEN 0
• SNCA 0
• STK11 0
• TLR4 0
• TTR 0
• VEGF 0
• YAP 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Litvánia· EU contribution 196 976 EUR· until 2029. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  From Stool to Solutions: Diagnose, Decode, Disruptors, and Deliver Interventions for the Human Gut Microbiota in Neurodegenerative Diseases. (GUT-4D)

  Universita Degli Studi del Piemonte Orientale Amedeo Avogadro· Vercelli, Olaszország· EU contribution 1 568 130 EUR· until 2030. szept.· 8 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unraveling the impact of RNA-editing in neurodegeneration: a focus on TDP-43 related frontotemporal dementia. (NeuroEDIT)

  Asociacion Instituto de Investigacion Sanitaria Biogipuzkoa· Donostia-San Sebastian, Spanyolország· EU contribution 194 075 EUR· until 2028. aug.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  POLYMND: Polyamine dysregulation in Motor Neuron Disease as a targetable driver of astrocyte–neuron dysfunction

  The Chancellor Masters and Scholars of the University of Cambridge· Cambridge, Egyesült Királyság· EU contribution 276 188 EUR· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  Engineered Humanized Spinal Cord Construct for Advancing Health and Disease Research (SpineCraft)

  Fundacio Institut de Bioenginyeria de Catalunya· Barcelona, Spanyolország· EU contribution 2 743 700 EUR· until 2031. márc.

  The disease is named only in the funder's project summary, not in the title.

5 of 14 running projects, newest first. Listed amounts together: 25,3 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 7
• Organoids 7
• Mendelian Randomization Analysis 18
• CRISPR-Cas Systems 8
• Gene Expression Profiling 23
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 6
• Proteomics 29
• Metabolomics 7
• Mass Spectrometry 6
• Flow Cytometry 2
• Immunohistochemistry 5
• Liquid Biopsy 2
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 57
• Machine Learning 18
• Deep Learning 7
• Cohort Studies 80
• Genome-Wide Association Study 24

• Metabolomic analyses of amyotrophic lateral sclerosis, muscle cramps, and TJ-68 treatment.

  Metabolomics, 2026. júl.

• Anchoring ALS Prognosis: Neurofilament Light Chain Outperforms Inflammatory, Metabolic, and CNS Barrier Biomarkers in the METABALS Cohort.

  Mol Neurobiol, 2026. máj.

• Integrated multi-omics analysis reveals gut dysbiosis and altered energy metabolism in Chinese ALS patients.

  Microbiol Spectr, 2026. ápr.

• Lifestyle-Associated Metabolic Signature Predicts the Risk of Amyotrophic Lateral Sclerosis.

  Muscle Nerve, 2026. febr.

• Untargeted metabolomics based on LC-MS and GC-MS reveal metabolic reprogramming and putative biomarkers in amyotrophic lateral sclerosis.

  Chin Med J (Engl), 2025. dec.

• Metabolic reprogramming in amyotrophic lateral sclerosis ependymal stem cells by FM19G11 nanotherapy.

  Sci Rep, 2025. nov.

• Multi-omics integration in disease research.

  Prog Brain Res, 2025. aug.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.